About abcellera biologics inc - ABCL
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
ABCL At a Glance
AbCellera Biologics, Inc.
150 West
Vancouver, British Columbia V5Y 1G6
| Phone | 1-604-559-9005 | Revenue | 75.13M | |
| Industry | Biotechnology | Net Income | -146,412,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 160.563% | |
| Fiscal Year-end | 12 / 2026 | Employees | 562 | |
| View SEC Filings |
ABCL Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.598 |
| Price to Book Ratio | 1.063 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.21 |
| Enterprise Value to Sales | 8.046 |
| Total Debt to Enterprise Value | 0.237 |
ABCL Efficiency
| Revenue/Employee | 133,679.715 |
| Income Per Employee | -260,519.573 |
| Receivables Turnover | 0.49 |
| Total Asset Turnover | 0.055 |
ABCL Liquidity
| Current Ratio | 11.324 |
| Quick Ratio | 11.226 |
| Cash Ratio | 8.713 |
ABCL Profitability
| Gross Margin | 61.637 |
| Operating Margin | -288.977 |
| Pretax Margin | -236.39 |
| Net Margin | -194.883 |
| Return on Assets | -10.775 |
| Return on Equity | -14.475 |
| Return on Total Capital | -13.189 |
| Return on Invested Capital | -13.184 |
ABCL Capital Structure
| Total Debt to Total Equity | 14.812 |
| Total Debt to Total Capital | 12.901 |
| Total Debt to Total Assets | 10.554 |
| Long-Term Debt to Equity | 14.211 |
| Long-Term Debt to Total Capital | 12.377 |